Teens with NF try video coaching to boost mood and health
NCT ID NCT03873610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two 8-week stress management programs delivered via secure video calls for 196 adolescents aged 12–17 with neurofibromatosis (NF1 or NF2). The goal was to see if these programs could improve emotional, social, and physical quality of life. Both programs taught coping skills for stress and NF symptoms, and the study measured changes using standard quality-of-life questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Stress and symptom management programs (behavioral intervention via videoconferencing)
- What this could lead to
- If successful, this could provide a practical, home-based way to help teens with neurofibromatosis better cope with stress and improve their quality of life.
- What could go wrong
- This is a completed behavioral study, not a drug trial, so it won't change the underlying disease. Results may not apply to all teens with NF, and improvements may be modest or short-lived.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
196 people
The number who actually took part.
- Started
-
Dec 2019
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Has a diagnosis of NF1 or NF2 and is between the ages of 12-17 * Is capable of completing and fully understanding the informed consent process/assent and the study procedures and assessments in English; has parental approval for participation * English speaking and at least a 3rd grade self-reported and parent reported reading level * Self reported/parent reported difficulties coping with stress and NF symptoms Exclusion Criteria: * Has major medical co-morbidity not NF related expected to worsen in the next 12 months * Recent (within past 3 months) change in antidepressant medication * Recent participation in cognitive behavioral therapy or relaxation therapy (within past 3 months) * Has significant mental health diagnosis requiring immediate treatment (e.g., untreated bipolar disorder, psychotic disorder, active substance dependence) * Unable or unwilling to complete assessments electronically via REDCap * Unable or unwilling to participate in group videoconferencing sessions * Unable or unwilling to participate along with at least 1 parent in a video screening session
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neurofibromatoses are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02140, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- Drug combo aims to shrink NF2 tumors and save hearing
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- Antioxidant drug shows promise for kids with NF1